Two Innovative Biopharma Companies Surge Over 100% on Hong Kong Debut

　　【Pharmaceutical Network Medical Stock Market] Since 2026, there has been a surge in IPOs of pharmaceutical and health enterprises on the Hong Kong Stock Exchange (HKEX). According to data, as of May 7, more than 50 biopharmaceutical companies have submitted their prospectuses to the HKEX this year. Notably, on May 13, two more pharmaceutical companies were listed on the HKEX, with their stock prices both skyrocketing over 100%.
 

On May 13, IMPACT Therapeutics was officially listed on the Main Board of the Hong Kong Stock Exchange. On the first day of listing, the share price of IMPACT Therapeutics opened high and continued to strengthen. As of the midday break on May 13, the company's share price was HK$43.76 per share, an increase of 117.71% over the offering price. The company offered 41,977,000 H shares globally this time, with a final offer price of HK$20.10 per share, raising a total of approximately HK$844 million. After deducting expenses, the net proceeds were approximately HK$760 million.
 

IMPACT Therapeutics is a commercial-stage, innovation-driven biotech company that has long focused on the research and development of precision cancer therapies based on the Synthetic Lethality mechanism. According to the company’s strategic plan, the proceeds from this fundraising will mainly be used for global clinical development, regulatory approval, and commercialization of the core product Senaparib, ongoing clinical development of key products IMP1734 and IMP9064, research and development activities for other pipeline assets, development and continuous expansion of the R&D platform, as well as supplementing working capital, among others.
 

According to reports, Senaparib is an oral PARP1/2 inhibitor that received approval from the National Medical Products Administration (NMPA) in January 2025 for marketing in China. It is indicated for adult patients with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer as maintenance therapy following complete or partial response to first-line platinum-based chemotherapy. In December 2025, Senaparib was included in the National Reimbursement Drug List (NRDL). In August 2025, the Marketing Authorization Application (MAA) for Senaparib in Europe was officially accepted by the European Medicines Agency (EMA).
 

On May 13, METiS TechBio officially listed on the Hong Kong Stock Exchange, with the closing price surging over 126% above the offering price, reaching a market capitalization of approximately 27.4 billion Hong Kong dollars. According to disclosures, METiS TechBio's IPO involved a global issuance of 201 million shares, with a final offer price of 10.5 Hong Kong dollars per share, raising a total of 2.112 billion Hong Kong dollars.
 

The net proceeds of this offering will be allocated as follows: 50% to the core technology R&D of AI infrastructure and the AI nanomaterials platform, 20% to advancing self-developed pipeline clinical trials; the remaining portion will be distributed across animal health and anti-aging sectors, establishing a global AI nanomaterials industry ecosystem, with the rest of the funds used for daily operations and general corporate purposes.
 

METiS TechBio focuses on AI-driven innovation in nanomaterials and targeted drug delivery. Its core competitiveness stems from the proprietary platform NanoForge, an AI-powered nanodelivery platform that integrates a self-generated lipid library of over ten million structurally diverse compounds. It also encompasses foundational AI models, the METiS intelligent agent, quantum chemistry and molecular dynamics simulations, as well as an AI-driven high-throughput screening platform.
 

Industry analysts believe that the simultaneous listing of IMPACT Therapeutics and METiS TechBio on the Hong Kong Stock Exchange, with both closing over 100% higher, is the result of multiple factors such as track scarcity, commercialization expectations, and capital rush. However, it should be noted that the subsequent trend and development prospects of the companies still need to be observed based on the actual performance of their core products.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.